BioXcel Therapeutics (BTAI) Stock Price

BioXcel Therapeutics Price

NASDAQ·CLOSED
0.85USD-0.03 (-3.49 %)
Market closed

Over the last 5 years BioXcel Therapeutics grew revenue by 666.3% annually, reaching 642,000.00 USD. For BioXcel Therapeutics, the net margin of -10,887.4% is up versus -337,481,500.0% a few years ago. The consensus 12-month price target for BioXcel Therapeutics is 12.24 USD, about 1,335.3% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus. The stock trades about 8% above its 52-week low.

BioXcel Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioXcel Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioXcel Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioXcel Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioXcel Therapeutics Stock Price History
DateBioXcel Therapeutics Price
8/5/20260.85 USD
8/4/20260.88 USD
8/3/20260.85 USD
7/31/20260.81 USD
7/30/20260.79 USD
7/29/20260.81 USD
7/27/20260.87 USD
7/23/20260.87 USD
7/22/20260.88 USD
7/21/20260.90 USD
7/20/20260.88 USD
7/17/20260.89 USD
7/16/20260.87 USD
7/15/20260.92 USD
7/14/20261.03 USD
7/13/20260.89 USD
7/10/20260.82 USD
7/9/20260.84 USD
7/8/20260.84 USD
7/7/20261.04 USD
7/6/20261.24 USD
7/2/20261.38 USD
7/1/20261.37 USD
6/30/20261.41 USD
6/29/20261.40 USD
6/26/20261.31 USD
6/25/20261.25 USD
6/24/20261.31 USD
6/23/20261.26 USD
6/22/20261.25 USD
6/18/20261.20 USD
6/17/20261.19 USD
6/16/20261.20 USD
6/15/20261.16 USD
6/12/20261.14 USD
6/11/20261.11 USD
6/10/20261.09 USD
6/9/20261.07 USD
6/8/20261.11 USD
6/5/20261.11 USD
6/4/20261.23 USD
6/3/20261.16 USD
6/2/20261.19 USD
6/1/20261.19 USD
5/29/20261.17 USD
5/28/20261.26 USD
5/27/20261.31 USD
5/26/20261.22 USD
5/22/20261.13 USD
5/21/20261.14 USD
5/20/20261.09 USD
5/19/20261.08 USD
5/18/20261.13 USD
5/15/20261.14 USD
5/14/20261.21 USD
5/13/20261.19 USD
5/12/20261.19 USD
5/11/20261.20 USD
5/8/20261.22 USD
5/7/20261.24 USD
5/6/20261.30 USD
5/5/20261.25 USD
5/4/20261.26 USD
5/1/20261.20 USD
4/30/20261.23 USD
4/29/20261.04 USD
4/28/20261.06 USD
4/27/20261.09 USD
4/24/20261.06 USD
4/23/20261.12 USD
4/22/20261.15 USD
4/21/20261.15 USD
4/20/20261.20 USD
4/17/20261.15 USD
4/16/20261.07 USD
4/15/20261.05 USD
4/14/20261.06 USD
4/13/20261.02 USD
4/10/20261.06 USD
4/9/20261.08 USD
4/8/20261.10 USD
4/7/20261.09 USD
4/6/20261.14 USD
4/2/20261.18 USD
4/1/20261.22 USD
3/31/20261.34 USD
3/30/20261.21 USD
3/27/20261.26 USD
3/26/20261.37 USD
3/25/20261.43 USD
3/24/20261.43 USD
3/23/20261.47 USD
3/20/20261.51 USD
3/19/20261.60 USD
3/18/20261.65 USD
3/17/20261.73 USD
3/16/20261.54 USD
3/13/20261.49 USD
3/12/20261.55 USD
3/11/20261.57 USD
3/10/20261.55 USD
3/9/20261.73 USD
3/6/20261.48 USD
3/5/20261.61 USD
3/4/20261.65 USD
3/3/20261.60 USD
3/2/20261.63 USD
2/27/20261.67 USD
2/26/20261.76 USD
2/25/20261.66 USD
2/24/20261.64 USD
2/23/20261.63 USD
2/20/20261.57 USD
2/19/20261.62 USD
2/18/20261.58 USD
2/17/20261.58 USD
2/13/20261.58 USD
2/12/20261.54 USD
2/11/20261.62 USD
2/10/20261.66 USD
2/9/20261.57 USD
2/6/20261.50 USD
2/5/20261.37 USD
2/4/20261.49 USD
2/3/20261.57 USD
2/2/20261.58 USD
1/30/20261.59 USD
1/29/20261.62 USD
1/28/20261.68 USD
1/27/20261.77 USD
1/26/20261.77 USD
1/23/20261.82 USD
1/22/20261.81 USD
1/21/20261.84 USD
1/20/20261.89 USD
1/16/20261.84 USD
1/15/20261.91 USD
1/14/20261.99 USD
1/13/20262.05 USD
1/12/20262.02 USD
1/9/20262.01 USD
1/8/20262.00 USD
1/7/20262.04 USD
1/6/20261.74 USD
1/5/20261.79 USD
1/2/20261.70 USD
12/31/20251.60 USD
12/30/20251.53 USD
12/29/20251.56 USD
12/26/20251.66 USD
12/24/20251.71 USD
12/23/20251.73 USD
12/22/20251.74 USD
12/19/20251.73 USD
12/18/20251.83 USD
12/17/20251.80 USD
12/16/20251.88 USD
12/15/20251.87 USD
12/12/20252.01 USD
12/11/20252.07 USD
12/10/20252.19 USD
12/9/20252.13 USD
12/8/20252.20 USD
12/5/20252.07 USD
12/4/20252.09 USD
12/3/20251.91 USD
12/2/20251.87 USD
12/1/20252.06 USD
11/28/20252.25 USD
11/26/20252.08 USD
11/25/20251.91 USD
11/24/20251.95 USD
11/21/20251.91 USD
11/20/20251.79 USD
11/19/20251.74 USD
11/18/20251.84 USD
11/17/20251.83 USD
11/14/20251.63 USD
11/13/20251.61 USD
11/12/20251.71 USD
11/11/20252.02 USD
11/10/20251.93 USD
11/7/20251.83 USD
11/6/20251.78 USD
11/5/20251.86 USD
11/4/20251.86 USD
11/3/20251.90 USD
10/31/20252.05 USD
10/30/20252.02 USD
10/29/20252.07 USD
10/28/20252.18 USD
10/27/20252.28 USD
10/24/20252.33 USD
10/23/20252.26 USD
10/22/20252.22 USD
10/21/20252.20 USD
10/20/20252.29 USD
10/17/20252.31 USD
10/16/20252.46 USD
10/15/20252.68 USD
10/14/20252.62 USD
10/13/20252.61 USD
10/10/20252.54 USD
10/9/20252.78 USD
10/8/20252.66 USD
10/7/20252.50 USD
10/6/20252.55 USD
10/3/20252.53 USD
10/2/20252.64 USD
10/1/20252.57 USD
9/30/20252.56 USD
9/29/20252.62 USD
9/26/20252.70 USD
9/25/20252.82 USD
9/24/20252.58 USD
9/23/20252.47 USD
9/22/20252.78 USD
9/19/20252.99 USD
9/18/20253.01 USD
9/17/20252.90 USD
9/16/20252.99 USD
9/15/20253.17 USD
9/12/20253.11 USD
9/11/20253.39 USD
9/10/20253.52 USD
9/9/20253.58 USD
9/8/20254.23 USD
9/5/20253.79 USD
9/4/20253.57 USD
9/3/20253.62 USD
9/2/20253.80 USD
8/29/20254.05 USD
8/28/20254.10 USD
8/27/20253.96 USD
8/26/20255.24 USD
8/25/20255.16 USD
8/22/20254.98 USD
8/21/20255.23 USD
8/20/20255.04 USD
8/19/20254.92 USD
8/18/20255.67 USD
8/15/20255.48 USD
8/14/20254.75 USD
8/13/20255.60 USD
8/12/20256.80 USD
8/11/20256.40 USD
8/8/20254.04 USD
8/7/20253.41 USD
Access this data via the Eulerpool API
Get Free API Key

BioXcel Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
1.38 M USD
-165.74 M USD
-179.05 M USD
Jan 1, 2024
2.27 M USD
-67.25 M USD
-59.60 M USD
Jan 1, 2025
642,000.00 USD
-52.91 M USD
-69.90 M USD
Jan 1, 2026 (e)
1.69 M USD
-1.01 M USD
-37.54 M USD
Jan 1, 2027 (e)
25.74 M USD
-15.44 M USD
-38.05 M USD
Jan 1, 2028 (e)
63.30 M USD
-37.98 M USD
-17.28 M USD
Jan 1, 2029 (e)
178.80 M USD
-107.28 M USD
-13.56 M USD
Jan 1, 2030 (e)
399.40 M USD
-239.64 M USD
32.37 M USD

BioXcel Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 7, 2026, 9:52 AM
 
REVENUEM USD
REVENUE GROWTH%
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––––1.002.00–1.0025.0063.00178.00399.00
–––––––––100.00––2,400.00152.00182.54124.16
–-2.00-4.00-19.00-33.00-82.00-106.00-160.00-165.00-67.00-52.00-1.00-15.00-37.00-107.00-239.00
––––––––-16,500.00-3,350.00–-100.00-60.00-58.73-60.11-59.90
–-2.00-4.00-19.00-32.00-82.00-106.00-165.00-179.00-59.00-69.00-37.00-38.00-17.00-13.0032.00
––100.00375.0068.42156.2529.2755.668.48-67.0416.95-46.382.70-55.26-23.53-346.15
12.211.000.870.981.131.521.7528.071.843.0412.2112.2112.2112.2112.2112.21
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioXcel Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioXcel Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioXcel Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioXcel Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioXcel Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioXcel Therapeutics stock margins

The BioXcel Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioXcel Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioXcel Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
74.45 %
- %
- %
Jan 1, 2022
94.67 %
-42,685.87 %
-44,201.87 %
Jan 1, 2023
8.70 %
-12,010.07 %
-12,974.86 %
Jan 1, 2024
5.43 %
-2,967.56 %
-2,630.14 %
Jan 1, 2025
74.45 %
-8,241.90 %
-10,887.38 %
Jan 1, 2026 (e)
74.45 %
-60.00 %
-2,221.55 %
Jan 1, 2027 (e)
74.45 %
-60.00 %
-147.85 %
Jan 1, 2028 (e)
74.45 %
-60.00 %
-27.29 %

BioXcel Therapeutics Stock Revenue, EBIT, Earnings per Share

The BioXcel Therapeutics earnings per share therefore indicates how much revenue BioXcel Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-61.15 USD
-60.97 USD
Jan 1, 2022
0.01 USD
-5.70 USD
-5.91 USD
Jan 1, 2023
0.75 USD
-90.05 USD
-97.28 USD
Jan 1, 2024
0.75 USD
-22.13 USD
-19.61 USD
Jan 1, 2025
0.05 USD
-4.33 USD
-5.73 USD
Jan 1, 2026 (e)
0.08 USD
-0.08 USD
-1.72 USD
Jan 1, 2027 (e)
1.18 USD
-1.26 USD
-1.74 USD
Jan 1, 2028 (e)
2.89 USD
-3.11 USD
-0.79 USD

BioXcel Therapeutics business model & stock analysis

BioXcel Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

BioXcel Therapeutics Employees
Details
Date
BioXcel Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

BioXcel Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioXcel Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

BioXcel Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioXcel Therapeutics shares outstanding

The number of shares of BioXcel Therapeutics was 12.21 M in 2025. This indicates how many shares BioXcel Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
1.75 M Stocks
Jan 1, 2022
28.07 M Stocks
Jan 1, 2023
1.84 M Stocks
Jan 1, 2024
3.04 M Stocks
Jan 1, 2025
12.21 M Stocks
Jan 1, 2026 (e)
12.21 M Stocks
Jan 1, 2027 (e)
12.21 M Stocks
Jan 1, 2028 (e)
12.21 M Stocks

BioXcel Therapeutics stock splits

In BioXcel Therapeutics's history, there have been no stock splits.

Current BioXcel Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
81.82 % (9)
Hold
9.09 % (1)
Sell
9.09 % (1)
12M Price Target
12.24
Last Price
0.85
Currency
USD
12M Return Potential
1,335.27 %
LTM Return
0 %

BioXcel Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
4/2/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/5/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
9/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
9/12/2025
Mizuho
Mizuho
MaintainedNeutral31
8/28/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/19/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/15/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/15/2025
LUCID CAPITAL MARKETS
LUCID CAPITAL MARKETS
MaintainedBuy–
6/23/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
1/30/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

BioXcel Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.52USD-261,803.00USD-2026 Q2
5/11/2026-0.49USD-356,235.00USD-2026 Q1
3/25/2026-0.77USD-165,240.00USD-2025 Q4
11/14/2024-0.55USD-1.33 MUSD-2024 Q3
5/6/2024-1.04USD-612,000.00USD-2024 Q1
3/7/2024-0.92USD-745,752.00USD-2023 Q4
11/8/2023-1.46USD-4.79 MUSD-2023 Q3
8/7/2023-1.61USD-9.73 MUSD-2023 Q2
5/8/2023-1.54USD-7.26 MUSD-2023 Q1
3/8/2023-1.40USD-3.19 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the BioXcel Therapeutics stock

22/100
9
Environment
29
Social
27
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

BioXcel Therapeutics shareholder structure

% Name
4.70075%
Millennium Management LLC
Millennium Management LLC
1.29904%
Oaktree Capital Management, L.P.
Oaktree Capital Management, L.P.
0.36862%
Murchinson Ltd.
Murchinson Ltd.
0.18236%
UBS Financial Services, Inc.
UBS Financial Services, Inc.
0.13489%
SLT Holdings LLC
SLT Holdings LLC
0.12886%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.

BioXcel Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
97.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
38.23%
Krishnan Nandabalan
Krishnan Nandabalan
SEC ↗
32.50%
Vimal Mehta
Vimal Mehta
SEC ↗
29.20%
BioXcel LLC
BioXcel LLC
SEC ↗
10.65%
FMR LLC
FMR LLC
SEC ↗
8.40%
Integrated Core Strategies (US) LLC
Integrated Core Strategies (US) LLC
SEC ↗
7.05%
Armistice Capital, LLC
Armistice Capital, LLC
SEC ↗
6.03%
SSGA FUNDS MANAGEMENT, INC.
SSGA FUNDS MANAGEMENT, INC.
SEC ↗
5.53%
Robert Atchinson
Robert Atchinson
SEC ↗
5.53%
Phillip Gross
Phillip Gross
SEC ↗
5.53%
Adage Capital Partners, L.P.
Adage Capital Partners, L.P.
SEC ↗

BioXcel Therapeutics Executives and Management Board

12 members · avg. age 62 · 8 % women

FY

Dr. Frank Yocca (69)

Executive Vice President, Chief Scientific Officer

1.15 M USD

Management

VM

Dr. Vimal Mehta (64)

President, Chief Executive Officer, Director · since 2017

1.12 M USD
JR

Mr. Javier Rodriguez (53)

Senior Vice President, Chief Legal Officer, Corporate Secretary

1.01 M USD
RS

Mr. Richard Steinhart (67)

Chief Financial Officer, Senior Vice President

994,094.00 USD
EK

Mr. Erik Kopp

Investor Relations · since 2025

–

Board of Directors

DM

Mr. David Mack (54)

Independent Director

215,619.00 USD
PM

Dr. Peter Mueller (68)

Lead Independent Chairman of the Board

150,410.00 USD
SL

Dr. Sandeep Laumas (56)

Independent Director

112,910.00 USD
MM

Mr. Michael Miller (67)

Independent Director

90,410.00 USD
MV

Dr. Michal Votruba (59)

Independent Director

90,410.00 USD
JB

Ms. June Bray (71)

Independent Director

85,410.00 USD

Frequently asked questions about BioXcel Therapeutics

Analysts currently set an average price target of 14.89 USD for the BioXcel Therapeutics stock (median: 12.24 USD), implying +1,646.2 % versus the latest price. The consensus is based on 11 analyst ratings.

BioXcel Therapeutics Analyst Price Targets 2026

11 analysts currently rate the BioXcel Therapeutics stock: 9 recommend buying, 1 holding and 1 selling. For 2026, analysts expect BioXcel Therapeutics to generate revenue of 1.69 M USD and earnings per share of -3.08 USD.

BioXcel Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the BioXcel Therapeutics share trades at 0.74 EUR (0.85 USD).

The BioXcel Therapeutics share (BTAI) is listed on 4 stock exchanges, including: NASDAQ (BTAI), Frankfurt (BX2.F), München (BX2.MU), Düsseldorf (BX2.DU).

No history available for BioXcel Therapeutics.

The expected revenue of BioXcel Therapeutics is 1.69 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BioXcel Therapeutics is -37.54 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BioXcel Therapeutics is currently -0.28. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioXcel Therapeutics stock.

The price-to-sales ratio (P/S) of BioXcel Therapeutics is currently 6.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioXcel Therapeutics stock.

The Eulerpool Quality Score for BioXcel Therapeutics is 3/10.

The ISIN of BioXcel Therapeutics is US09075P2048. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of BioXcel Therapeutics is A2JF20. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of BioXcel Therapeutics is BTAI. The ticker symbol is used to trade BioXcel Therapeutics shares on the stock exchange.

BioXcel Therapeutics paid dividends every year for the past 0 years.

BioXcel Therapeutics is assigned to the 'Health' sector.

The dividends of BioXcel Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of BioXcel Therapeutics

Our stock analysis for BioXcel Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioXcel Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioXcel Therapeutics Stock
BioXcel Therapeutics Revenue→
BioXcel Therapeutics Stock
BioXcel Therapeutics Net Income→
BioXcel Therapeutics Stock
BioXcel Therapeutics P/E→
BioXcel Therapeutics Stock
BioXcel Therapeutics P/S→
BioXcel Therapeutics Stock
BioXcel Therapeutics EBIT→
BioXcel Therapeutics Stock
BioXcel Therapeutics Dividend→
BioXcel Therapeutics Stock
BioXcel Therapeutics Directors Dealings→
BioXcel Therapeutics Stock
BioXcel Therapeutics Stocks→
BioXcel Therapeutics Stock
BioXcel Therapeutics Market capitalization→
BioXcel Therapeutics Stock
BioXcel Therapeutics Debt→
BioXcel Therapeutics Stock
BioXcel Therapeutics Liabilities→
BioXcel Therapeutics Stock
BioXcel Therapeutics Equity→
BioXcel Therapeutics Stock
BioXcel Therapeutics AAQS→
BioXcel Therapeutics Stock
BioXcel Therapeutics Employees→
BioXcel Therapeutics Stock
BioXcel Therapeutics ROE→
BioXcel Therapeutics Stock
BioXcel Therapeutics ROA→
BioXcel Therapeutics Stock
BioXcel Therapeutics ROCE→
BioXcel Therapeutics Stock
BioXcel Therapeutics News→
BioXcel Therapeutics Stock
BioXcel Therapeutics Analyst Price Targets→

Health Stocks

BioxytranBioVieBistos CoBiovica InternationalBITComputerBioventusBlack Diamond TherapeuticsBioventixBlau FarmaceuticaBiotronBlinkLabBioToxTech CoAll Stocks A–Z →